Bernstein downgrades packaged food stocks as inflation squeezes margins and GLP-1 drugs curb food consumption, hitting consumer staples ETFs like XLP.
The Consumer Staples Select Sector SPDR Fund (XLP) holds major packaged food stocks. Bernstein's downgrade of the sector due to inflation and GLP-1 drug risks signals downward pressure on XLP, which is heavily weighted toward companies like Procter & Gamble, Coca-Cola, and PepsiCo that are exposed to these headwinds.
XLP tracks consumer staples stocks, many of which are packaged food companies. Bernstein's bearish outlook signals potential underperformance in the sector, likely leading to selling pressure on XLP in the short term.
Snack and beverage companies like Mondelez, PepsiCo, and Coca-Cola could see reduced demand if GLP-1 drugs curb snacking and sugary drink consumption. XLP holds significant positions in these names.
Bernstein Research turned bearish on packaged food stocks, citing persistent inflation squeezing margins and the growing adoption of GLP-1 weight-loss drugs like Ozempic and Wegovy that reduce consumer food demand. The double headwind threatens earnings growth and valuation multiples across the sector. Investors rotated out of consumer staples, with the XLP ETF facing downside risk as the downgrade prompts selling pressure on major holdings.
Bernstein cited two major headwinds: high inflation eroding profit margins and the growing use of GLP-1 drugs like Ozempic, which are reducing consumer food intake and demand for packaged foods.
Rising input costs for ingredients, packaging, and labor compress margins, while consumers trade down to cheaper alternatives or reduce discretionary food purchases.
GLP-1 drugs suppress appetite, leading to lower calorie consumption. This shift could structurally reduce demand for high-calorie packaged snacks and meals, hurting sales.